RecruitingNCT05685069

Prevalence of Attributable Etiology and Modifiable Stroke Risk Factors in Patients With Covert Brain Infarctions

Prevalence of Attributable Etiology and Modifiable Stroke Risk Factors in Patients With Covert Brain Infarctions (CBI-registry)


Sponsor

Insel Gruppe AG, University Hospital Bern

Enrollment

230 participants

Start Date

Mar 1, 2019

Study Type

OBSERVATIONAL

Conditions

Summary

The CBI registry is a prospective, interdisciplinary, multimodal observational registry of patients with covert brain infarction. Methods: A standardized workup in analogy to manifest ischemic stroke including cerebral MRI, long-term rhythm monitoring (3 x 7 days ECG), echocardiography, laboratory work-up and risk factor assessment as well as noninvasive angiography of the cervical and intracranial arteries will be performed.


Eligibility

Min Age: 16 Years

Inclusion Criteria5

  • Any clinically silent ischemic lesions of the brain parenchyma detected on neuroimaging defined according to established criteria as either:
  • DWI positive lesions: Focus of restricted diffusion (high DWI signal and low ADC value) occurring in either white or gray matter, located in the cerebrum, cerebellum, or brain stem AND not satisfying the diagnostic criteria for MS OR
  • Cavitatory Lesions: ≥ 3 mm in size that follow CSF on all sequences that are slit or wedge shaped with an irregular margin AND NOT longitudinally aligned with perforating vessels or with a multiple, bilateral symmetrical distribution OR
  • T2W hyperintense/T1W hypointense lesions: Focal lesion with high T2W signal and low T1W signal that have prior evidence of restricted diffusion; OR present within cortical gray matter or deep gray matter nuclei OR a lesion that is new, compared with an MRI performed within 3 months OR T2W hyper/T1W hypointense lesions in the white matter, which are discontinuous but associated with the classic confluent periventricular T2 intense change of leukoaraiosis (Fazekas ≥2) AND NOT satisfying the diagnostic criteria for MS or with a significant patient history of severe trauma, radiation, drug toxicity, or carbon monoxide poisoning
  • Informed Consent as documented by signature by patient or legally authorized representative

Exclusion Criteria9

  • Projected life expectancy of less than 2 years,
  • Contraindication to MRI,
  • Patients with a history of symptoms compatible with an AIS/TIA attributable to the lesion observed, covert neurological deficits are allowed,
  • Patient is already included in another clinical trial that will affect the objectives of this study,
  • Patient's lack of accountability, inability to appreciate the nature, meaning and consequences of the study and to formulate his/her own wishes correspondingly,
  • Women who are pregnant or breast feeding or intention to become pregnant during the course of the study,
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,
  • Contraindications to any of the routine procedures, e.g. inability to obtain neurovascular ultrasound examination,
  • Known or suspected non-compliance, drug or alcohol abuse

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(2)

Centre Hospitalier Universitaire de Tours

Tours, France

Inselspital Bern

Bern, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05685069


Related Trials